ArticleThe Journal of clinical investigation2013
Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 186 citations in OpenAlex.
- Investigating the Role of Anti-Leukemia Inhibitory Factor Antibody on Cytokine Profile in a Mouse Model of Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Hypoxia-induced RCOR2 promotes macrophage M2 polarization and CD8Journal for immunotherapy of cancer · 2025Article
- EC359 Enhances Trametinib Efficacy inBiomolecules · 2025Article
- Cancer-Associated Fibroblasts Interact with Schwann Cells for Tumor Perineural Invasion by Oral Squamous Cell Carcinoma.Neuroscience bulletin · 2025Article
- Bushen Jianpi Tiaoxue Decoction (BJTD) inhibits the LIF-mTOR signaling axis to regulate mitochondrial function and alleviate cyclophosphamide-induced diminished ovarian reserve.Apoptosis : an international journal on programmed cell death · 2025Article
- Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models.Journal for immunotherapy of cancer · 2025Article
- The causal relationships between inflammatory cytokines, blood metabolites, and thyroid cancer: a two-step Mendelian randomization analysis.Discover oncology · 2025Article
- Article
- Inflammation in cancer: therapeutic opportunities from new insights.Molecular cancer · 2025Review
- Article
- Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Significance of LIF/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast Cancer.Cancers · 2024Article
- A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selection.CPT: pharmacometrics & systems pharmacology · 2024Article
- Discovery and validation of colorectal cancer tissue-specific methylation markers: a dual-center retrospective cohort study.Clinical epigenetics · 2024Article
- Impact of anti leukemia inhibitory factor antibody on immune related gene expression in breast cancer Balb/c mouse model.Scientific reports · 2024Article
- Antagonist anti-LIF antibody derived from naive human scFv phage library inhibited tumor growth in mice.BMC immunology · 2024Article
- Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.NPJ precision oncology · 2024Article
- Emerging Therapies for Glioblastoma.Cancers · 2024Review
- The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Leukemia inhibitory factor suppresses hepatic de novo lipogenesis and induces cachexia in mice.Nature communications · 2024Article
58 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioresistance of EBV-associated nasopharyngeal carcinoma (NPC) is associated with poor prognosis for patients with this form of cancer. Here, we found that NPC patients had increased serum levels of leukemia inhibitory factor (LIF) and that higher LIF levels correlated with local tumor recurrence. Furthermore, in vitro studies with NPC cells and in vivo xenograft mouse studies demonstrated that LIF critically contributes to NPC tumor growth and radioresistance. Using these model systems, we found that LIF treatment activated the mTORC1/p70S6K signaling pathway, enhanced tumor growth, inhibited DNA damage responses, and enhanced radioresistance. Treatment with either soluble LIF receptor (sLIFR), a LIF antagonist, or the mTOR inhibitor rapamycin reversed LIF-mediated effects, resulting in growth arrest and increased sensitivity to γ irradiation. Immunohistochemical (IHC) analyses of human NPC biopsies revealed that LIF and LIFR were overexpressed in tumor cells and that LIF expression correlated with the presence of the activated p-p70S6K. Finally, we found that the EBV-encoded protein latent membrane protein 1 (LMP1) enhances LIF production. Together, our findings indicate that LIF promotes NPC tumorigenesis and suggest that serum LIF levels may predict local recurrence and radiosensitivity in NPC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.